SEC FORM
3
SEC Form 3
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
| 4208 SIX FORKS ROAD, SUITE 920 |
|
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
09/28/2022
|
3. Issuer Name and Ticker or Trading Symbol
IDERA PHARMACEUTICALS, INC.
[ IDRA ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| X |
Director |
|
10% Owner |
|
Officer (give title below) |
X |
Other (specify below) |
| See Remarks |
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Form filed by One Reporting Person |
| X |
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
1. Name and Address of Reporting Person*
| 4208 SIX FORKS ROAD, SUITE 920 |
|
(Street)
|
1. Name and Address of Reporting Person*
| 4208 SIX FORKS ROAD, SUITE 920 |
|
(Street)
|
| Explanation of Responses: |
| Remarks: |
|
| No securities are beneficially owned. |
|
/s/ S. Halle Vakani, Attorney-in-Fact for NQ POF V GP, Ltd., General Partner of NovaQuest Co-Investment Fund XV, L.P. |
10/03/2022 |
|
/s/ S. Halle Vakani, Attorney-in-Fact for NQ POF V GP, Ltd. |
10/03/2022 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby
constitutes and appoints each of Daniel S. Porper, S. Halle
Vakani and Lorna A. Knick, and each of them acting alone,
signing singly and with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the
Undersigned's capacity as a duly authorized
representative of NovaQuest Co-Investment Fund XV, L.P.
and NQ POF V GP, Ltd. (the "Company"), Forms ID, 3, 4
and 5, Update Passphrase Acknowledgement (and any
amendments thereto) in accordance with Section 16(a) of
the Securities Exchange Act of 1934, as amended (the
"1934 Act") and Schedules 13D and/or Schedules 13G (and
any amendment thereto) in accordance with the 1934 Act,
and the rules promulgated thereunder;
(2) do and perform any and all acts for and on behalf of
the undersigned which may be necessary or desirable to
complete and execute any such Form ID, 3, 4 and 5,
Update Passphrase Acknowledgement and Schedules 13D
and/or Schedules 13G (and any amendments thereto) and
to file timely such form with the United States
Securities and Exchange Commission and any stock exchange
or similar authority; and
(3) take any other action of any type whatsoever in
connection with the foregoing which in the opinion of
such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the
undersigned, it being understood that the documents
executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall
be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-
fact full power and authority to do and perform any and every
act and thing whatsoever requisite, necessary or proper to be
done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full
power of substitution or revocation, hereby ratifying and
confirming that all such attorneys-in-fact, or such attorneys-
in-facts' substitute or substitutes, shall lawfully do or
cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the 1934 Act.
This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms
ID, 3, 4 and 5 and Schedules 13D and Schedules 13G with
respect to the undersigned's holdings of and transactions in
securities issued by Idera Pharmaceuticals, Inc., unless earlier
revoked by the undersigned, in a signed writing delivered to
each of the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused
this Power of Attorney to be executed as of this 30th day of
September 2022.
NOVAQUEST CO-INVESTMENT FUND XV, L.P.
By: NQ POF V GP, Ltd., its general partner
By: /s/ John Bradley
Name: John Bradley
Title: Director
NQ POF V GP, LTD.
By: /s/ John Bradley
Name: John Bradley
Title: Director
